Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed cholangiocarcinoma.~* Radiographically measurable or evaluable disease per RECIST v1.1.~* Tumor assessment for FGF/FGFR gene alteration status.~* Documented disease progression after at least 1 line of prior systemic therapy.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.~* Life expectancy ≥ 12 weeks.~Exclusion Criteria:~* Prior receipt of a selective FGFR inhibitor.~* History of and/or current evidence of ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, excepting calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcifications.~* Current evidence of clinically significant corneal or retinal disorder confirmed by ophthalmologic examination.~* Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug. Topical ketoconazole will be allowed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A Pemigatinib (Type: EXPERIMENTAL): Pemigatinib in subjects with FGFR2 translocation with a documented fusion partner in central laboratory report
- Cohort B Pemigatinib (Type: EXPERIMENTAL): Pemigatinibin subjects with other FGF/FGFR alterations
- Cohort C Pemigatinib (Type: EXPERIMENTAL): Pemigatinib in subjects negative for FGF/FGFR alteration

Based on this trial design, predict the completion outcome and termination type (if applicable).